Effects of 3-O-[6-deoxy-3-O-methyl- β-D-allopyranosyl-(1 4)-β-D-canaropyranosyl]-17β-marsdenin on selected indices of cardiovascular diseases in mouse

AbstractSome anticancer pregnane glycosides, e.g., 3-O-[6-deoxy-3-O-methyl- β-d-allopyranosyl-(1 → 4)-β-d-canaropyranosyl]-17β-marsdenin (3DMACM), have been isolated fromGongronema latifolium leaves which have not been evaluated for their effects on the cardiovascular system. Thus, this study was carried out to evaluate the effects of 3DMACM on selected indices of cardiovascular diseases in albino mice. Forty mice were randomly divided into four groups (ten mice each). Group A mice were orally administered 5% DMSO while mice in groups B, C, and D were orally administered 0.25, 0.5, and 1 mg/kg body weight of the compound for 14 days, after which various indices of cardiovascular diseases were determined. The results revealed that the total cholesterol, triacylglycerol, very low density lipoprotein-, and high-density lipoprotein-cholesterol concentrations in the plasma and heart Na+-K+-ATPase activity were significantly reduced (p <  0.05) at the doses of 0.25 and 1 mg/kg body weight of the compound compared to controls. Also, atherogenic index, plasma LDH activity, and heart Mg2+-ATPase activity of the mice were significantly (p <  0.05) reduced at all doses of the compound compared to controls. Heart and plasma creatine kinase activities and heart Ca2+-Mg2+-ATPase activity of mice were significantly (p <  0.05) reduced at doses higher than 0.25 mg/kg body weight of the compound compared to controls. AST activities in the heart and plasma of mice...
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research